Lv5
1320 积分 2024-01-11 加入
拓培非格司亭与硫培非格司亭用于淋巴瘤及多发性骨髓瘤患者自体外周血干细胞动员的疗效与安全性比较:一项前瞻性、多中心、随机对照研究
7天前
已完结
拓培非格司亭 4mg 与硫培非格司亭 6mg 用于淋巴瘤/骨髓瘤自体外周血干细胞动员的疗效与安全性比较
7天前
已关闭
Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the Phase 1/2 BRUIN study
4个月前
已关闭
Luvometinib: First Approval
4个月前
已完结
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015
6个月前
已完结
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015
6个月前
已完结
Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission
6个月前
已完结
SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions
7个月前
已完结
Azacitidine maintenance in AML post induction and posttransplant
7个月前
已完结
皖公网安备34019202002308
